PatentJul 31, 2026, 04:13 PM
Veraxa Biotech Strengthens Patent Portfolio; 50+ Patents Secured
AI Summary
Veraxa Biotech AG announced significant updates to its core patent portfolio, including the filing of new applications for its BiTAC-TCE and BiTAC-ADC platforms in H1 2026. The company now holds over 50 granted patents across 26 families in 14 countries, with new applications expected to extend protection through at least 2047. This expansion aims to safeguard its innovative technologies, including click chemistry and conjugation, for next-generation cancer therapies.
Key Highlights
- First BiTAC®-related patent applications filed in H1 2026.
- New applications cover composition of matter and proprietary payload platform.
- Additional patents secured in contributing technology areas including click chemistry and conjugation.
- Company now holds over 50 granted owned or exclusively licensed patents in 14 countries.
- Patent portfolio is spread across 26 patent families.
- Recently filed applications, once granted, are expected to protect core technology through at least 2047.
- Focus on BiTAC-TCE and BiTAC-ADC platforms for novel cancer therapies.
Price Impact
More from VRXA